HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis b: Clinical outcomes and durability

Gut

Volumn 63, Issue 8, 2014, Pages 1325-1332

  Kim, Gi Ae ^a   Lim, Young Suk ^a   An, Jihyun ^a   Lee, Danbi ^a   Shim, Ju Hyun ^a   Kim, Kang Mo ^a   Lee, Han Chu ^a   Chung, Young Hwa ^a   Lee, Yung Sang ^a   Suh, Dong Jin ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; ENTECAVIR; HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; VIRUS DNA;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOLOGICAL PARAMETERS; KOREA; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REVERTANT; SEROCLEARANCE; SEROCONVERSION; TREATMENT DURATION; TREATMENT OUTCOME;

HEPATITIS B;

ADULT; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; DNA, VIRAL; FEMALE; FOLLOW-UP STUDIES; GUANINE; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; KAPLAN-MEIER ESTIMATE; LAMIVUDINE; LIVER CIRRHOSIS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; TIME FACTORS;

EID: 84904042319     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2013-305517     Document Type: Article

References (50)

1. Perz JF, Armstrong GL, Farrington LA, et al. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006;45:529-38. (Pubitemid 44307383)
2. Schiff ER. Prevention of mortality from hepatitis B and hepatitis C. Lancet 2006;368:896-7. (Pubitemid 44331366)
3. Liaw YF, Sheen IS, Chen TJ, et al. Incidence, determinants and significance of delayed clearance of serum HBs AG in chronic hepatitis B virus infection: A prospective study. Hepatology 1991;13:627-31.
4. Gish RG, Chang TT, Lai CL, et al. Loss of HBs AG antigen during treatment with entecavir or lamivudine in nucleoside-naive HBeAg-positive patients with chronic hepatitis B. J Viral Hepat 2010;17:16-22.
5. Chang TT, Lai CL, Kew Yoon S, et al. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2010;51:422-30.
6. Hadziyannis SJ, Sevastianos V, Rapti I, et al. Sustained responses and loss of HBs AG in HBeAg-negative patients with chronic hepatitis B who stop long- Term treatment with adefovir. Gastroenterology 2012;143:629-36.
7. Marcellin P, Gane E, Buti M, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: A 5-year open-label follow-up study. Lancet 2013;381:468-75.
8. Buster EH, Flink HJ, Cakaloglu Y, et al. Sustained HBeAg and HBs AG loss after long- Term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b. Gastroenterology 2008;135:459-67.
9. Moucari R, Korevaar A, Lada O, et al. High rates of HBs AG seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: A long- Term follow-up study. J Hepatol 2009;50:1084-92.
10. Fattovich G, Giustina G, Sanchez- Tapias J, et al. Delayed clearance of serum HBs AG in compensated cirrhosis B: relation to interferon alpha therapy and disease prognosis. European Concerted Action on Viral Hepatitis (EUROHEP). Am J Gastroenterol 1998;93:896-900. (Pubitemid 29076972)
11. Chu CM, Liaw YF. HBs AG seroclearance in asymptomatic carriers of high endemic areas: Appreciably high rates during a long- Term follow-up. Hepatology 2007;45:1187-92.
12. Yuen MF, Wong DK, Fung J, et al. HBs AG Seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma. Gastroenterology 2008;135:1192-9.
13. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009;50:661-2.
14. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012;57:167-85.
15. Hsu CW, Yeh CT, Chang ML, et al. Identification of a hepatitis B virus S gene mutant in lamivudine- Treated patients experiencing HBs AG seroclearance. Gastroenterology 2007;132:543-50.
16. Hong SP, Kim NK, Hwang SG, et al. Detection of hepatitis B virus YMDD variants using mass spectrometric analysis of oligonucleotide fragments. J Hepatol 2004;40:837-44. (Pubitemid 38507366)
17. Bae SH, Yoon SK, Jang JW, et al. Hepatitis B virus genotype C prevails among chronic carriers of the virus in Korea. J Korean Med Sci 2005;20:816-20.
18. Kleinbaum DG, Klein M. Survival analysis: A self-learning text (statistics for biology and health). Springer 2005:235-45.
19. Yuen MF, Wong DK, Sablon E, et al. HBs AG seroclearance in chronic hepatitis B in the Chinese: virological, histological, and clinical aspects. Hepatology 2004;39:1694-701. (Pubitemid 38702671)
20. Chien RN, Yeh CT, Tsai SL, et al. Determinants for sustained HBeAg response to lamivudine therapy. Hepatology 2003;38:1267-73.
21. Chan HL, Hui AY, Wong ML, et al. Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma. Gut 2004;53:1494-8. (Pubitemid 39265273)
22. Yang HI, Yeh SH, Chen PJ, et al. Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma. J Natl Cancer Inst 2008;100:1134-43.
23. Yu MW, Yeh SH, Chen PJ, et al. Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: A prospective study in men. J Natl Cancer Inst 2005;97:265-72.
24. Arase Y, Ikeda K, Suzuki F, et al. Long- Term outcome after hepatitis B surface antigen seroclearance in patients with chronic hepatitis B. Am J Med 2006;119:71.9-16.
25. Chen YC, Sheen IS, Chu CM, et al. Prognosis following spontaneous HBs AG seroclearance in chronic hepatitis B patients with or without concurrent infection. Gastroenterology 2002;123:1084-9.
26. Yeh CT. Development of HBV S gene mutants in chronic hepatitis B patients receiving nucleotide/nucleoside analogue therapy. Antivir Ther 2010;15:471-5.
27. Lok AS, Hussain M, Cursano C, et al. Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e antigen-negative patients receiving lamivudine therapy. Hepatology 2000;32:1145-53.
28. Torresi J, Earnest-Silveira L, Civitico G, et al. Restoration of replication phenotype of lamivudine-resistant hepatitis B virus mutants by compensatory changes in the "fingers" subdomain of the viral polymerase selected as a consequence of mutations in the overlapping S gene. Virology 2002;299:88-99. (Pubitemid 35007514)
29. Bartholomeusz A, Locarnini S. Hepatitis B virus mutations associated with antiviral therapy. J Med Virol 2006;78(Suppl 1):52-5.
30. Yeh CT, Chang MH, Lai HY, et al. Identification of a novel pre-S2 mutation in a subgroup of chronic carriers with spontaneous clearance of hepatitis B virus surface antigen. J Gastroenterol Hepatol 2003;18:1129-38.
31. Sloan RD, Ijaz S, Moore PL, et al. Antiviral resistance mutations potentiate hepatitis B virus immune evasion through disruption of its surface antigen a determinant. Antivir Ther 2008;13:439-47. (Pubitemid 352016737)
32. Louisirirotchanakul S, Khupulsup K, Akraekthalin S, et al. Comparison of the technical and clinical performance of the Elecsys HBs AG II assay with the Architect, AxSym, and Advia Centaur HBs AG screening assays. J Med Virol 2010;82:755-62.
33. Arase Y, Suzuki F, Suzuki Y, et al. Long- Term presence of HBV in the sera of chronic hepatitis B patients with HBs AG seroclearance. Intervirology 2007;50:161-5. (Pubitemid 46597275)
34. Chu CM, Liaw YF. Prevalence of and risk factors for hepatitis B viremia after spontaneous hepatitis B surface antigen seroclearance in hepatitis B carriers. Clin Infect Dis 2012;54:88-90.
35. Zoutendijk R, Hansen BE, van Vuuren AJ, et al. Serum HBs AG decline during long- Term potent nucleos(t)ide analogue therapy for chronic hepatitis B and prediction of HBs AG loss. J Infect Dis 2011;204:415-18.
36. Chan HL, Thompson A, Martinot-Peignoux M, et al. Hepatitis B surface antigen quantification: why and how to use it in 2011- A core group report. J Hepatol 2011;55:1121-31.
37. Boni C, Laccabue D, Lampertico P, et al. Restored function of HBV-specific T cells after long- Term effective therapy with nucleos(t)ide analogues. Gastroenterology 2012;143:963-73.
38. Boni C, Penna A, Bertoletti A, et al. Transient restoration of anti-viral T cell responses induced by lamivudine therapy in chronic hepatitis B. J Hepatol 2003;39:595-605. (Pubitemid 37204661)
39. Jaroszewicz J, Ho H, Markova A, et al. Hepatitis B surface antigen (HBs AG) decrease and serum interferon-inducible protein-10 levels as predictive markers for HBs AG loss during treatment with nucleoside/nucleotide analogues. Antivir Ther 2011;16:915-24.
40. Heathcote EJ, Marcellin P, Buti M, et al. Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology 2011;140:132-43.
41. Seto WK, Wong DK, Fung J, et al. Reduction of hepatitis B surface antigen levels and hepatitis B surface antigen seroclearance in chronic hepatitis B patients receiving 10 years of nucleoside analogue therapy. Hepatology 2013;58:923-31.
42. Kobayashi M, Hosaka T, Suzuki F, et al. Seroclearance rate of hepatitis B surface antigen in 2, 112 patients with chronic hepatitis in Japan during long- Term follow-up. J Gastroenterol 2013:Epub ahead of print.
43. Fasano M, Lampertico P, Marzano A, et al. HBV DNA suppression and HBs AG clearance in HBeAg negative chronic hepatitis B patients on lamivudine therapy for over 5 years. J Hepatol 2012;56:1254-8.
44. Wursthorn K, Jung M, Riva A, et al. Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients. Hepatology 2010;52:1611-20.
45. Moucari R, Mackiewicz V, Lada O, et al. Early serum HBs AG drop: A strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology 2009;49:1151-7.
46. Chan HL, Wong GL, Chim AM, et al. Prediction of off- Treatment response to lamivudine by serum hepatitis B surface antigen quantification in hepatitis B e antigen-negative patients. Antivir Ther 2011;16:1249-57.
47. Liu J, Lee MH, Batrla-Utermann R, et al. A predictive scoring system for the seroclearance of HBs AG in HBeAg-seronegative chronic hepatitis B patients with genotype B or C infection. J Hepatol 2013;58:853-60.
48. Seto WK, Wong DK, Fung J, et al. A large case-control study on the predictability of hepatitis B surface antigen levels three years before hepatitis B surface antigen seroclearance. Hepatology 2012;56:812-19.
49. Tseng TC, Liu CJ, Yang HC, et al. Determinants of spontaneous surface antigen loss in hepatitis B e antigen-negative patients with a low viral load. Hepatology 2011;55:68-76.
50. Chevaliez S, Hezode C, Bahrami S, et al. Long- Term hepatitis B surface antigen (HBs AG) kinetics during nucleoside/nucleotide analogue therapy: finite treatment duration unlikely. J Hepatol 2013;58:676-83.